Study identifier:D8480C00039
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Two Part Study in Japanese Patients with mCRC, Consisting of an Open-label Phase I Part to assess the Safety and Tolerability of cediranib (AZD2171) in combination with FOLFOX followed by a Phase II, Randomised, Double-blind, Parallel Group Study to Assess the Efficacy of cediranib (AZD2171) in combination with FOLFOX
Metastatic Colorectal Cancer
Phase 1/2
No
AZD2171, FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin), Placebo Cediranib
All
172
Interventional
18 Years +
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 May 2012 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
Arms | Assigned Interventions |
---|---|
Active Comparator: FOLFOX + Cediranib 20 mg FOLFOX + Cediranib 20 mg | Drug: AZD2171 oral tablet Other Name: cediranib Other Name: RECENTIN™ Drug: FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin) intravenous infusion Other Name: Eloxatin® Other Name: 5-FU Other Name: Leucovorin |
Active Comparator: FOLFOX + Cediranib 30 mg FOLFOX + Cediranib 30 mg | Drug: AZD2171 oral tablet Other Name: cediranib Other Name: RECENTIN™ Drug: FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin) intravenous infusion Other Name: Eloxatin® Other Name: 5-FU Other Name: Leucovorin |
Placebo Comparator: FOLFOX + Placebo Cediranib FOLFOX + Placebo Cediranib | Drug: FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin) intravenous infusion Other Name: Eloxatin® Other Name: 5-FU Other Name: Leucovorin Drug: Placebo Cediranib oral tablet |